Novozymes, the world’s largest producer of industrial enzymes, announces its results for the first nine months of 2015. Sales grew by 4 percent organically and by 14 percent in DKK compared with 9M 2014. EBIT grew by 15 percent, and the EBIT margin was 27.7 percent. Net profit grew by 11 percent, and free cash flow before acquisitions came in at DKK 2,022 million. In Q3 alone, sales grew by 3 percent organically and by 11 percent in DKK compared with Q3 2014.
“Our performance was in line with expectations nine months into the year: record earnings on a relatively low top line growth,” says Peder Holk Nielsen, president and CEO of Novozymes. “We’re on track to meet the full-year organic sales and profit outlook, as we continue to focus our efforts on driving innovation and sales growth.”
More information is available here: http://novozymes.com/en/investor/news-and-announcements/Pages/9M-sales-and-profit-in-line-with-August-expectations;-full-year-outlook-narrowed-.aspx
